ADIL

Adial Pharmaceuticals (ADIL)

Adial Pharmaceuticals Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ADIL

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/15	21 : 30	GlobeNewswire Inc.	Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update	NASDAQ:ADIL	Adial Pharmaceuticals Inc
2024/05/15	06 : 03	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ADIL	Adial Pharmaceuticals Inc
2024/04/22	21 : 30	GlobeNewswire Inc.	Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office	NASDAQ:ADIL	Adial Pharmaceuticals Inc
2024/04/10	21 : 30	GlobeNewswire Inc.	Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder	NASDAQ:ADIL	Adial Pharmaceuticals Inc
2024/04/02	21 : 30	GlobeNewswire Inc.	Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update	NASDAQ:ADIL	Adial Pharmaceuticals Inc
2024/03/02	09 : 00	GlobeNewswire Inc.	Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds	NASDAQ:ADIL	Adial Pharmaceuticals Inc
2024/02/28	23 : 30	GlobeNewswire Inc.	Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office	NASDAQ:ADIL	Adial Pharmaceuticals Inc
2024/02/15	05 : 22	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:ADIL	Adial Pharmaceuticals Inc
2024/02/13	23 : 15	GlobeNewswire Inc.	Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office	NASDAQ:ADIL	Adial Pharmaceuticals Inc
2024/01/26	06 : 30	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:ADIL	Adial Pharmaceuticals Inc
2024/01/25	14 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:ADIL	Adial Pharmaceuticals Inc
2024/01/19	06 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ADIL	Adial Pharmaceuticals Inc
2024/01/18	22 : 30	GlobeNewswire Inc.	Adial Announces Appointment of Tony Goodman as Chief Operating Officer	NASDAQ:ADIL	Adial Pharmaceuticals Inc
2024/01/17	06 : 17	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ADIL	Adial Pharmaceuticals Inc
2024/01/13	06 : 51	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:ADIL	Adial Pharmaceuticals Inc
2023/12/20	23 : 00	GlobeNewswire Inc.	Adial Pharmaceuticals Receives Final Reimbursement Payment from Adovate	NASDAQ:ADIL	Adial Pharmaceuticals Inc
2023/12/13	06 : 36	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:ADIL	Adial Pharmaceuticals Inc
2023/12/09	01 : 08	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:ADIL	Adial Pharmaceuticals Inc
2023/11/30	06 : 47	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ADIL	Adial Pharmaceuticals Inc
2023/11/30	06 : 05	GlobeNewswire Inc.	Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement	NASDAQ:ADIL	Adial Pharmaceuticals Inc
2023/11/29	06 : 10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ADIL	Adial Pharmaceuticals Inc
2023/11/24	23 : 24	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:ADIL	Adial Pharmaceuticals Inc
2023/11/20	21 : 46	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:ADIL	Adial Pharmaceuticals Inc
2023/11/20	14 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:ADIL	Adial Pharmaceuticals Inc
2023/11/15	07 : 02	GlobeNewswire Inc.	Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update	NASDAQ:ADIL	Adial Pharmaceuticals Inc
2023/11/09	06 : 05	Edgar (US Regulatory)	Form S-1 - General form for registration of securities under the Securities Act of 1933	NASDAQ:ADIL	Adial Pharmaceuticals Inc
2023/11/06	20 : 14	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ADIL	Adial Pharmaceuticals Inc
2023/10/31	21 : 30	GlobeNewswire Inc.	Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss “New Aspects in Substance Use Treatment” at The Annual International Society of Addiction Medicine Conference	NASDAQ:ADIL	Adial Pharmaceuticals Inc
2023/10/31	06 : 24	Edgar (US Regulatory)	Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]	NASDAQ:ADIL	Adial Pharmaceuticals Inc
2023/10/31	06 : 18	Edgar (US Regulatory)	Form 8-K/A - Current report: [Amend]	NASDAQ:ADIL	Adial Pharmaceuticals Inc